Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma

被引:7
作者
Pugh-Toole, Morgan [1 ,2 ]
Nicolela, Anna P. [3 ]
Nersesian, Sarah [2 ,4 ]
Leung, Brendan M. [1 ,2 ,5 ,6 ]
Boudreau, Jeanette E. [1 ,2 ,4 ]
机构
[1] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada
[2] Beatrice Hunter Canc Res Inst, Halifax, NS, Canada
[3] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada
[4] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4R5, Canada
[5] Dalhousie Univ, Sch Biomed Engn, Halifax, NS, Canada
[6] Dalhousie Univ, Dept Appl Oral Sci, Halifax, NS, Canada
关键词
High-grade serous carcinoma; Ovarian cancer; Natural killer cells; Immunotherapy; Combination therapy; DNA-DAMAGE RESPONSE; NK CELLS; DRUG-DELIVERY; CANCER; CHEMOTHERAPY; ANTIBODY; BEVACIZUMAB; RESISTANCE; SIGNATURES; PROGNOSIS;
D O I
10.1007/s11864-021-00929-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Opinion statement Ovarian cancer (OC), especially high-grade serous cancer (HGSC), is a highly heterogeneous malignancy with limited options for curative treatment and a high frequency of relapse. Interactions between OC and the immune system may permit immunoediting and immune escape, and current standard of care therapies can influence immune cell infiltration and function within the tumor microenvironment. Natural killer (NK) cells are involved in cancer immunosurveillance and immunoediting and can be activated by therapy, but deliberate approaches to maximize NK cell reactivity for treatment of HGSC are in their infancy. NK cells may be the ideal target for immunotherapy of HGSC. The diverse functions of NK cells, and their established roles in immunosurveillance, make them attractive candidates for more precise and effective HGSC treatment. NK cells' functional capabilities differ because of variation in receptor expression and genetics, with meaningful impacts on their anticancer activity. Studying HGSC:NK cell interactions will define the features that predict the best outcomes for patients with the disease, but the highly diverse nature of HGSC will likely require combination therapies or approaches to simultaneously target multiple, co-existing features of the tumor to avoid tumor escape and relapse. We expect that the ideal therapy will enable NK cell infiltration and activity, reverse immunosuppression within the tumor microenvironment, and enable effector functions against the diverse subpopulations that comprise HGSC.
引用
收藏
页码:210 / 226
页数:17
相关论文
共 93 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
    Andre, Pascale
    Denis, Caroline
    Soulas, Caroline
    Bourbon-Caillet, Clarisse
    Lopez, Julie
    Arnoux, Thomas
    Blery, Mathieu
    Bonnafous, Cecile
    Gauthier, Laurent
    Morel, Ariane
    Rossi, Benjamin
    Remark, Romain
    Breso, Violette
    Bonnet, Elodie
    Habif, Guillaume
    Guia, Sophie
    Lalanne, Ana Ines
    Hoffmann, Caroline
    Lantz, Olivier
    Fayette, Jerome
    Boyer-Chammard, Agnes
    Zerbib, Robert
    Dodion, Pierre
    Ghadially, Hormas
    Jure-Kunkel, Maria
    Morel, Yannis
    Herbst, Ronald
    Narni-Mancinelli, Emilie
    Cohen, Roger B.
    Vivier, Eric
    [J]. CELL, 2018, 175 (07) : 1731 - +
  • [3] STAT1-associated intratumoural T(H)1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer
    Au, Katrina K.
    Le Page, Cecile
    Ren, Runhan
    Meunier, Liliane
    Clement, Isabelle
    Tyrishkin, Kathrin
    Peterson, Nichole
    Kendall-Dupont, Jennifer
    Childs, Timothy
    Francis, Julie-Ann
    Graham, Charles H.
    Craig, Andrew W.
    Squire, Jeremy A.
    Mes-Masson, Anne-Marie
    Koti, Madhuri
    [J]. JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2016, 2 (04) : 259 - 270
  • [4] Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion
    Ayuso, Jose M.
    Rehman, Shujah
    Virumbrales-Munoz, Maria
    McMinn, Patrick H.
    Geiger, Peter
    Fitzgerald, Cate
    Heaster, Tiffany
    Skala, Melissa C.
    Beebe, David J.
    [J]. SCIENCE ADVANCES, 2021, 7 (08):
  • [5] Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer
    Banville, Allyson C.
    Wouters, Maartje C. A.
    Oberg, Ann L.
    Goergen, Krista M.
    Maurer, Matthew J.
    Milne, Katy
    Ashkani, Jahanshah
    Field, Emma
    Ghesquiere, Chanel
    Jones, Steven J. M.
    Block, Matthew S.
    Nelson, Brad H.
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 160 (02) : 520 - 529
  • [6] High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
    Bareche, Yacine
    Pommey, Sandra
    Carneiro, Mayra
    Buisseret, Laurence
    Cousineau, Isabelle
    Thebault, Pamela
    Chrobak, Pavel
    Communal, Laudine
    Allard, David
    Robson, Simon C.
    Mes-Masson, Anne-Marie
    Provencher, Diane
    Lapointe, Rejean
    Stagg, John
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
  • [7] The biology of ovarian cancer: new opportunities for translation
    Bast, Robert C., Jr.
    Hennessy, Bryan
    Mills, Gordon B.
    [J]. NATURE REVIEWS CANCER, 2009, 9 (06) : 415 - 428
  • [8] BECKERHAPAK MK, 2021, CANCER IMMUNOL RES, V1002
  • [9] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615
  • [10] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550